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REVIEW
Abstract: The appearance of hair plays an important role in people’s overall physical
appearance and self-perception. With today’s increasing life-expectations, the desire to look
youthful plays a bigger role than ever. The hair care industry has become aware of this and is
delivering active products directed towards meeting this consumer demand. The discovery of
pharmacological targets and the development of safe and effective drugs also indicate strategies
of the drug industry for maintenance of healthy and beautiful hair. Hair aging comprises
weathering of the hair shaft, decrease of melanocyte function, and decrease in hair production.
The scalp is subject to intrinsic and extrinsic aging. Intrinsic factors are related to individual
genetic and epigenetic mechanisms with interindividual variation: prototypes are familial
premature graying, and androgenetic alopecia. Currently available pharmacologic treatment
modalities with proven efficacy for treatment of androgenetic alopecia are topical minoxidil
and oral finasteride. Extrinsic factors include ultraviolet radiation and air pollution.
Experimental evidence supports the hypothesis that oxidative stress also plays a role in hair
aging. Topical anti-aging compounds include photoprotectors and antioxidants. In the absence
of another way to reverse hair graying, hair colorants remain the mainstay of recovering lost
hair color. Topical liposome targeting for melanins, genes, and proteins selectively to hair
follicles are currently under investigation.
Keywords: hair weathering, graying, androgenetic alopecia, senescent alopecia, hair anti-
aging
“Aged? But he does not appear aged,
 just look, his hair has remained young!”
– Marcel Proust, Remembrance of Things Past
In today’s world, physical appearance and the notion of looking young and energetic
play a greater role than ever. Hair length, color, and style are important for people’s
physical appearance and self-perception. The condition and style of hair determine
how we discern the people we encounter, and how we are perceived by those we
come upon. Hair is not only intended to invoke male recognition of feminine appeal
and desirability, but it has even become a predicate upon which social success and
career opportunities are based. Our preoccupation with hair is further heightened as
our increasing life-expectancy fuels our desire to preserve youthfulness.
The study of hair aging focuses on two main streams of interest: on one hand, the
aesthetic problem of aging hair and its management, in other words everything that
happens outside the skin; on the other hand, the biological problem of aging hair, in
terms of microscopic, biochemical (hormonal, enzymatic), and molecular changes,
in other words, the “secret life” of the hair follicle in the depth of the skin. Scientists
interested in the biology of hair growth and pigmentation have exposed the hair follicle
as a highly accessible and unique model that offers unequaled opportunities to the
gerontologist for the study of age-related effects.
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Finally, the discovery of pharmacological targets and the
development of safe and effective drugs for the treatment of
alopecia indicate strategies of the drug industry for
maintenance of healthy and beautiful hair in the young and
old.
It is the aim of this paper to review the manifestations of
aging hair and the basis for pharmacologic interventions in
aging hair.
Aging of hair
Hair aging comprises weathering of the hair shaft, and aging
of the hair follicle. The former involves progressive
degeneration of the hair fiber from the root to the tip, while
the latter manifests as decrease of melanocyte function or
graying, and decrease in hair production in androgenetic
and senescent alopecia. The scalp is subject to intrinsic or
physiologic aging, and extrinsic or premature aging due to
external factors. Intrinsic factors are related to individual
genetic and epigenetic mechanisms with interindividual
variation. Prototypes are familial premature graying, and
androgenetic alopecia (AGA). Extrinsic factors include
ultraviolet radiation, air pollution, smoking, nutrition, and
lifestyle. Experimental evidence supports the hypothesis that
oxidative stress plays a major role in premature skin and
hair aging.
Hair weathering
Weathering represents the wear and tear that mainly affects
the free end of the growing hair fibre. Once the hair shaft
leaves the skin and grows longer, it undergoes some degree
of degeneration depending on the extent of environmental
and cosmetic damage. Since scalp hair has the longest hair
growing phase, it is subject to more damage than hairs at
other body sites. In normal hair, the damage is most
prominent only near the tip of scalp hair, which often appears
lusterless and paler than more proximal growth, with varying
degrees of split ends (trichoptilosis). The hair fibre with its
normal surface structure of overlapping cuticular cells is
potentially susceptible to friction damage from excessive
combing and brushing, particularly when wet. Associated
procedures may cause additional damage, in particular from
excessive heat “blown” or from curling irons applied to the
hair. Chemical treatment of hair, ie, bleaching, coloring,
perming, and straightening, is a major cause of exaggerated
hair weathering, since the cuticle becomes raised and
softened in the course of these procedures, and becoming
more vulnerable to mechanical abrasion. Loss of cuticle
leads to longitudinal fissures between exposed cortical cells,
ultimately resulting in hair fractures (trichorrhexis nodosa)
at these sites (Dawber 1996).
Graying
Hair graying (canities) is a natural age-associated feature.
The hair graying trait correlates closely with chronological
aging and occurs to varying degrees in all individuals. While
the normal incidence of hair graying is 34 ± 9.6 years in
Caucasians and 43.9 ± 10.3 years in Africans, it has been
described that, by 50 years of age, 50% of people have 50%
gray hair. This graying incidence appears irrespective of sex
and hair color. In men, graying usually begins at the temples
and in the sideburns. Women will usually start around the
perimeter of the hairline. Gradually, the gray works its way
back through the top, sides, and back of the hair. The rate at
which an individual turns gray depends on genetics. It is
not uncommon to observe kinships with marked early
graying throughout. Hair is said to gray prematurely if it
occurs before the age of 20 in Caucasians and before 30 in
Africans. While premature canities more commonly appear
without underlying pathology, presumably inherited in an
autosomal dominant manner, it has also been associated with
a similar cluster of autoimmune disorders as occurring in
vitiligo (eg, pernicious anemia, autoimmune thyroid disease)
and several rare syndromes with premature aging (eg,
Werner’s syndrome).
Although graying is understood as a loss of pigment in
the shaft, its cellular and molecular origins are incompletely
understood (overview in: Tobin and Paus 2001). The color
of hair mainly relies on the presence or absence of melanin
pigment. Skin and hair melanins are formed in cytoplasmic
organelles called melanosomes, produced by the
melanocytes, and are the product of a complex biochemical
pathway (melanogenesis) with tyrosinase being the rate-
limiting enzyme. It has been shown that gray hair has
undergone a marked reduction in melanogenically-active
melanocytes in the hair follicle (Commo et al 2004). The
net effect of this reduction is that fewer melanosomes are
incorporated into cortical keratinocytes of the hair shaft. In
addition, there appears also to be a defect of melanosome
transfer, as keratinocytes may not contain melanin despite
their proximity to melanocytes with remaining
melanosomes. This defect is further corroborated by the
observation of melanin debris in and sometimes around the
graying hair bulb. This anomaly is due to either defective
melanosomal transfer to the cortical keratinocytes or melaninClinical Interventions in Aging 2006:1(2) 123
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incontinence due to melanocyte degeneration. Eventually,
no melanogenic melanocytes remain in the hair bulb. This
decrease of melanin synthesis is associated with a decrease
in tyrosinase activity, as indicated by a reduced 3,4-
dihydroxyphenylalanine (DOPA) reaction. Ultrastructural
studies have shown that remaining melanocytes not only
contain fewer melanosomes, but the residual melanosomes
may be packaged within autophagolysosomes. This removal
of melanosomes into autophagolyosomes suggests that they
are defective, possibly with reactive melanin metabolites.
This interpretation is supported by the observation that
melanocytes in graying hair bulbs are frequently highly
vacuolated, a common cellular response to increased
oxidative stress. The extraordinary melanogenic activity of
pigmented bulbar melanocytes, continuing for up to 10 years
in some hair follicles, is likely to generate large amounts of
reactive oxygen species via the hydroxylation of tyrosine
and the oxidation of DOPA to melanin. If not adequately
removed by an efficient antioxidant system, an accumulation
of these reactive oxidative species will generate significant
oxidative stress. It is possible that the antioxidant system
becomes impaired with age leading to damage to the
melanocyte itself from its own melanogenesis-related
oxidative stress. Since mutations occur at a higher rate in
tissue exposed to high levels of oxidative stress, and these
accumulate with age, the induction of replicative senescence
with apoptosis is likely to be an important protective
mechanism against cell transformation.
Anecdotal evidence indicates that gray hair is coarser
and less manageable than pigmented hair. Moreover, gray
hair often fails to hold a temporary or permanent set, and is
more resistant to incorporating artificial color, both of which
suggest significant changes to the underlying substructure
of the hair fiber. Given the very close interaction of melanin
transferring-melanocytes with hair shaft-forming precortical
keratinocytes, it is conceivable that other functions of these
cell types are affected by this activity. One possibility is
that melanin transfer decreases keratinocyte turnover and
increases keratinocyte terminal differentiation. Indeed, white
beard hair has been shown to grow up to four times the rate
of adjacent pigmented hair (Nagl 1995). In this way, aging
hair follicles may reprogram their matrix keratinocytes to
increase production of medullary, rather than cortical,
keratinocytes. In fact the medulla is often enlarged and
collapsed, forming a central cavity in gray and white hairs
(van Neste 2004; van Neste and Tobin 2004). An
evolutionary basis for this increased medullation in senile
white hair may reflect the enhanced insulation provided by
these hairs which would confer an important benefit for
temperature regulation. In this way, it may compensate for
the loss of the sunlight-absorbing and thus heat-trapping
properties of melanized dark hair (Paus and Tobin 2001).
Besides being thicker and displaying a more developed
medulla, white hair was also found to have increased
sensitivity to weathering, increased cysteic acid residues and
decreased cystine, and increased fibre reactivity to reducing
and oxidizing agents. Whether these differences, seemingly
related to the lack of melanin and to the enlarged medulla,
are also directly responsible for the coarseness of white hair
and their relative resistance to hair setting and coloring, is
not clearly established.
Hair loss
Androgenetic alopecia, also referred to as male-pattern hair
loss or common baldness in men, and as female-pattern hair
loss (FPHL) in women, affects at least 50% of men by the
age of 50 years, and up to 70% of all males in later life
(Norwood 1975). Estimates of its prevalence in women have
varied widely, though recent studies claim that 16% of
women aged under 50 years are affected, increasing to a
proportion of 30%–40% of women aged 70 years and over
(Norwood 2001). The hair loss is heritable, androgen-
dependent, and occurs in a defined pattern. It is assumed
that the genetically predisposed hair follicles are the target
for androgen-stimulated hair follicle miniaturization, leading
to gradual replacement of large, pigmented hairs (terminal
hairs) by barely visible, depigmented hairs (vellus hairs) in
affected areas (overview in: Trüeb 2002). The result is a
progressive decline in visible scalp hair density. While male
pattern AGA is characterized by its typical bitemporal
recession of hair and balding vertex, FPHL is set apart by
its diffuse thinning of the crown and intact frontal hairline.
While the genetic involvement is pronounced, but poorly
understood, major advances have been achieved in
understanding principal elements of the androgen
metabolism involved in the pathogenesis of AGA (overview
in: Kaufman 1996): Androgen-dependent processes are
predominantly due to the binding of dihydrotestosterone
(DHT) to the androgen receptor (AR). Dihydrotestosterone-
dependent cell functions depend on the availability of weak
androgens, their conversion to more potent androgens via
the action of 5α-reductase, low enzymatic activity of
androgen inactivating enzymes, and functionally active AR
present in high numbers. The predisposed scalp exhibits highClinical Interventions in Aging 2006:1(2) 124
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levels of DHT, and increased expression of the AR.
Conversion of testosterone to DHT within the dermal papilla
plays a central role, while androgen-regulated factors
deriving from dermal papilla cells are believed to influence
growth of other components of the hair follicle. Since many
extrinsic hair growth-modulatory factors, such as androgens
(Randall et al 1992), apparently operate at least in part via
the dermal papilla, research is currently also focused on
identifying androgen-regulated factors deriving from dermal
papilla cells. Of the several factors that have been suggested
to play a role in hair growth, so far only insulin-like growth
factor (IGF-1) has been reported as altered in vitro by
androgens (Itami et al 1995), and stem cell factor (SCF) has
been found to be produced in higher amounts by androgen-
dependent beard cells than in control non-balding scalp cells,
presumably also in response to androgens (Hibberts et al
1996). Since SCF is the ligand for the cell surface receptor
c-kit on melanocytes, this may also play a role for hair
pigmentation.
The limited success rate of treatment of AGA with hair
growth promoters or modulators of androgen metabolism
means that further pathogenic pathways may be taken into
account. The implication of microscopic follicular
inflammation in the pathogenesis of AGA has recently
emerged from several independent studies (Jaworsky et al
1992; Whiting 1993; Mahé et al 2000). An early study
referred to an inflammatory infiltrate of activated T cells
and macrophages in the upper third of the hair follicles,
associated with an enlargement of the follicular dermal
sheath composed of collagen bundles (perifollicular
fibrosis), in regions of actively progressing alopecia
(Jaworsky et al 1992). Horizontal section studies of scalp
biopsies indicated that the perifollicular fibrosis is generally
mild, consisting of loose, concentric layers of collagen that
must be distinguished from cicatricial alopecia (Whiting
1993). The term “microinflammation” has been proposed
because the process involves a slow, subtle, and indolent
course, in contrast to the inflammatory and destructive
process in the classical inflammatory scarring alopecias
(Mahé et al 2000). An important question is how the
inflammatory reaction pattern is generated around the
individual hair follicle. Inflammation is regarded a multistep
process that may start from a primary event. The observation
of a perifollicular infiltrate in the upper follicle near the
infundibulum suggests that the primary causal event for the
triggering of inflammation might occur near the
infundibulum (Mahé et al 2000). On the basis of this
localization and the microbial colonization of the follicular
infundibulum with Propionibacterium sp., Staphylococcus
sp., Malassezia sp., or other members of the transient flora,
one could speculate that microbial toxins or antigens could
be involved in the generation of the inflammatory response.
Alternatively, keratinocytes themselves may respond to
chemical stress from irritants, pollutants, and ultraviolet
(UV) irradiation, by producing radical oxygen species and
nitric oxide, and by releasing intracellularly stored
interleukin (IL)-1α. This pro-inflammatory cytokine by itself
has been shown to inhibit the growth of isolated hair follicles
in culture (Philpott et al 1996). Moreover, adjacent
keratinocytes, which express receptors for IL-1, start to
engage the transcription of IL-1 responsive genes: mRNA
coding for IL-1β, tumor necrosis factor-α (TNFα), and IL-
1α, and for specific chemokine genes, such as IL-8, and
monocyte chemoattractant protein (MCP)-1 and MCP-3,
themselves mediators for the recruitment of neutrophils and
macrophages, have been shown to be upregulated in the
epithelial compartment of the human hair follicle (Mahé et
al 2000). Besides, adjacent fibroblasts are also fully equipped
to respond to such a pro-inflammatory signal. The
upregulation of adhesion molecules for blood-borne cells
in the capillary endothelia, together with the chemokine
gradient, drive the transendothelial migration of
inflammatory cells, which include neutrophils through the
action of IL-8, T cells and Langerhans cells at least in part
through the action of MCP-1. After processing of localized
antigen, Langerhans cells, or alternatively keratinocytes,
which may also have antigen presenting capabilities, could
then present antigen to newly infiltrating T lymphocytes and
induce T-cell proliferation. The antigens are selectively
destroyed by infiltrating macrophages, or natural killer cells.
On the occasion that the causal agents persist, sustained
inflammation is the result, together with connective tissue
remodeling, where collagenases, such as matrix
metalloproteinase (also transcriptionally driven by pro-
inflammatory cytokines) play an active role (Mahé et al
2000). Collagenases are suspected to contribute to the tissue
changes in perifollicular fibrosis. The significance of these
findings has remained controversial. However,
morphometric studies in patients with male pattern AGA
treated with minoxidil showed that 55% of those with
microinflammation had regrowth in response to treatment,
in comparison with 77% in those patients without
inflammation and fibrosis (Whiting 1993).
Finally, the relationship of FPHL to (male pattern) AGA
has been challenged. Arguments against FPHL representing
the female counterpart of male AGA are a probably mother-Clinical Interventions in Aging 2006:1(2) 125
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to-daughter transmission of FPHL, a significantly lower
incidence of FPHL in women than AGA in men (Norwood,
2001), occurrence of FPHL  in the absence of circulating
androgens (Orme et al 1999), lack of response to
antiandrogen therapy in normoandrogenemic premenopausal
women (Vexiau et al 2002), lack of response to 1mg oral
finasteride daily in postmenopausal women (Price et al
2000), and occurrence of male pattern AGA in women with
pathologically elevated androgen levels. It has been
suggested that the different pattern of hair loss in the majority
of women from that usually seen in men may be due to
differences in the relative levels of 5α-reductase, aromatase,
and androgen receptors in scalp hair follicles in women
compared with those in men (Sawaya and Price 1997).
In contrast to AGA, senile involutional or senescent
alopecia has been defined as nonandrogen-dependent hair
thinning found in those over 50 years of age (Kligman 1988).
Much like AGA, it involves a progressive decrease in the
number of anagen follicles and hair diameter. It frequently
occurs together with AGA, further complicating its
delineation from the latter. Some authors proposed that
senescent alopecia may result from cumulative physiological
degeneration of selected hair follicles. In healthy murine
skin they described clusters of perifollicular macrophages
as perhaps indicating the existence of a physiological
program of immunologically controlled hair follicle
degeneration by which malfunctioning follicles are removed
by programmed organ deletion (Eichmuller et al 1998). On
the other hand, in his original description, Kligman (1988)
proposed a pronounced inflammatory component in AGA,
but not in senescent alopecia. Moreover, Price et al (2001),
did not identify any “drop-out” of follicles in senescent
alopecia upon staining biopsies for elastin, whereas there
was less 5α-reductase enzyme activity in comparison with
AGA. Nevertheless, some forms of primary fibrosing
alopecia may represent pathological exaggeration of
immune-mediated, programmed organ deletion, resulting in
a follicular lichenoid reaction pattern, specifically
postmenopausal frontal fibrosing alopecia (Kossard 1994),
and fibrosing alopecia in a pattern distribution (Zinkernagel
and Trüeb 2000).
In their study on aging and hair cycles over an
exceptionally long duration of 8 to 14 years, Courtois et al
(1995) found a reduction in the duration of hair growth and
in the diameter of hair shafts, and a prolongation of the
interval separating the loss of a hair in telogen and the
emergence of a replacement hair in anagen (latency phase).
These phenomena resemble those observed in the course of
AGA, although their development is less marked, suggesting
AGA is a premature aging phenomenon. This aging process
was evidenced by a reduction in the number of hairs per
unit area and deterioration in the quality of scalp hair. The
reduction in density was manifested to different degrees in
different individuals. It amounted to less than 10% in 10
years in the individuals with the least alopecia, and was much
more pronounced in the balding subjects. The maximal
length of hair diminished as the subjects aged, in parallel
the hairs became finer. However, among nonbalding subjects,
there was a tendency for the proportion of thicker hairs to
increase. Finally, aging did not appear to follow a perfectly
regular course over time. Periods of stability, or even partial
remission, alternated with periods of more marked evolution,
perhaps reflected the influence of individual factors such as
the subject’s general health, life-style, and risk factors for
accelerated aging.
Role of UV radiation
Progressive thinning of scalp hair in AGA results in a gradual
decline in natural protection of the scalp from UV radiation
(UVR). While the consequences of sustained UVR on the
unprotected scalp are obvious and well appreciated,
specifically photocarcinogenesis and solar elastosis, the
effects of UVR on hair loss have widely been ignored.
However, clinical observations and theoretical
considerations suggest that UVR may have negative effects
(overview in: Trüeb 2003): acute telogen effluvium from
UVR has been described (Camacho et al 1996), and the
production of porphyrins by Propionibacterium sp. in the
pilosebaceous duct, with photoactivation of porphyrins
(Johnsson et al 1987) leading to oxidative tissue injury, may
contribute to follicular microinflammation operative at the
level of the follicular stem cells. Histopathologically
elastosis is regularly found in scalp biopsies, especially in
alopecic conditions. A recent study demonstrated a
relationship between the degree of scalp elastosis and
severity of AGA (Piérard-Franchimont et al 2002): the scalp
dermis was significantly thicker in AGA than in unaffected
control subjects. The difference was due to severe elastosis
in baldness. The earliest signs of solar elastosis preceded
hair thinning. When elastosis was thicker than 0.2mm, a
negative exponential correlation was found between hair
diameter and severity of solar elastosis.
Care of aging hair
While shampoos have been the most common form of
cosmetic hair treatment, primarily aimed at cleansing theClinical Interventions in Aging 2006:1(2) 126
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hair and scalp, today’s consumer expects more options. With
the cosmetic market being consumer driven, the industry
has become aware of this, and at the same time became
capable of delivering active compounds towards meeting
this consumer demand. The result are dermocosmetic agents
that achieve cosmetic benefits by some degree of physiologic
action. Current hair care products are tailored to the
variations associated with age, gender, hair quality, hair care
habit, and specific problems related to the superficial
condition of the scalp. Problems frequently associated with
aging hair are hair thinning, dryness, and damaged hair.
The mechanics of taking care of thin hair can be
rewarding. The first thing to be recommended is to shampoo
frequently, especially when hair is greasy. This will leave
the hair fluffy and give the illusion of thicker hair. Permanent
waves can make hair feel thicker and impart more body.
Also, gray hair that has become thinner will feel thicker
with hair color on it.
Dry hair is hair which does not have enough moisture. It
is difficult to style and has lost its shine. This is usually
because the cuticle has become heavily weathered and
porous, in damaged hair usually as a consequence of repeated
cosmetic procedures. The hair cortex is exposed and cannot
retain humidity. Treatment of dry and damaged hair consists
of intensive conditioning. Conditioners protect the edges of
the cuticle scales, although they cannot cure broken hairs
where the cortex fibers have burst out (trichorrhexis and
split ends). Hair care products (conditioning shampoos, hair
conditioners) designed for dry or damaged hair contain large
molecules that collect on the edges of the damaged scales
of the cuticle, helping to smooth over and fill in the fractures
and fissures (overview in: Bouillon 1996). They impart
softness, easier grooming, and luster to dry hair. They give
back smoothness, gloss, and manageability to damaged hair.
Cationic polymers, hydrolyzed proteins, and silicones, such
as dimethicone, are useful in this process. In addition,
panthenol is absorbed into the shaft and acts as a humefactant
by providing moisture. Constant research to find new
formulas is at the base of the progress achieved in the
development of effective hair care products. The recent
identification of different amino acid profiles in normal and
weathered hair, and the development of a system of amino
acids lost from the hair shaft in the course of weathering
and capable of being delivered from cosmetic formulations,
is an example (Gummer and Shiel 2004).
Abnormal hairs with inherent weakness are susceptible
to excessive weathering. Besides minimizing chemical and
physical trauma to the hair and special hair care measures,
specific and early treatment of AGA with progressive
weakening of the hair shaft using appropriate systemic and/
or topical pharmacologic therapy (see Possibilities for
prevention or reversal of hair loss) is thus of additional
benefit for those affected.
Pharmacologic and other
interventions in aging hair
Possibilities for reversal of hair graying
Temporary hair darkening has been reported after ingestion
of large doses of p-aminobenzoic acid (Sieve 1941;
Zarafonetis1950). Sieve (1941) gave 100mg three times
daily to 460 gray-haired individuals and noted a response
in 82%. Darkening was obvious within 2–4 months of
starting treatment. The hairs turned gray again 2–4 weeks
after stopping therapy. The mechanism of action has
remained unclear. Side effects were frequent, primarily
gastrointestinal upset.
In the absence of a natural way to reverse hair graying,
hair colorants are the mainstay of recovering lost hair color.
The major types of hair colors currently used are: temporary
(textile dyes), natural coloring (henna), semipermanent (low
molecular weight direct dyes), and permanent (aromatic
amines).
Temporary hair colorants consist of large complex
organic structures that do not penetrate the cuticle. The colors
are not intense but are capable of covering gray hair in a
subtle way. This may be a good way for an individual to
experiment with the coloring idea. The colorant washes out
with the next shampoo
Henna, obtained form the plant Lawsonia alba, is a
naturally occurring hair colorant. Although the color can
add red highlights to hair, occasionally it may come out
looking orange on gray hair.
Semipermanent colorants consist of small molecules that
penetrate the cuticle. These compounds color gray hair very
nicely, are easily applied in a lotion or foam at home, and
last for six to ten shampoos.
The most frequently used hair colorant is permanent hair
dye. In permanent hair coloring the formation of colored
molecules from their precursors occurs inside the hair fibers
as a result of oxidation by hydrogen peroxide. The advantage
of permanent color is that the color withstands normal hair
washing. Because new growth comes out, the roots need to
be touched up. There have been studies that raised the
possibility that long-term usage of permanent hair dyes
(particularly black dyes) may be associated with an increasedClinical Interventions in Aging 2006:1(2) 127
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risk of developing certain cancers. However, taken together
the evidence is insufficient to state with certainty whether
there is a link between using hair dye and cancer. A small
number of users may develop irritative and allergic contact
reactions (commonly due to p-phenylenediamine) that may
result in dermatitis and even hair loss.
Possibilities for prevention or reversal
of hair loss during aging
It has been known for over 30 years that minoxidil stimulates
hair growth, yet its mechanism of action on the hair follicle
is still poorly understood (overview in: Messenger and
Rundegren 2004). A number of in vitro effects of minoxidil
have been described in monocultures of various hair follicle
cell types including stimulation of cell proliferation,
inhibition of collagen synthesis, and stimulation of vascular
endothelial growth factor (VEGF) and prostaglandin
synthesis. In animal studies, topical minoxidil shortens the
resting phase (telogen) of the hair cycle, causing premature
entry of resting hair follicles into the growing phase
(anagen), and it probably has a similar action in humans.
Minoxidil may also cause prolongation of anagen and
increases hair follicle size. Clinical trials of topical 2% and
5% minoxidil in male and female hair loss have all shown
remarkably rapid increase in hair growth, measured by hair
counts or hair weight (Olsen et al 1985, 1987, 1990; Price
and Menefee 1990; De Villez et al 1994; Olsen, Dunlap, et
al 2002; Lucky et al 2004). The increase is evident within
6–8 weeks of treatment and has generally peaked by 12–16
weeks. However, topical minoxidil has not been studied in
the specific perspective of aging and senescent alopecia. In
an recent analysis of clinical trial data in 636 males and 630
females, a therapeutic benefit of topical 2 and 5% minoxidil
solution was compared with age, duration of balding, and
diameter of balding vertex area in males, and age and
duration of hair loss in females (Rundegren 2004). Age was
found to be the denominator for predicting treatment success
for both males and females. The younger subjects
experienced better efficacy than the older subjects although
clear treatment effects were noted also in the older age group.
Males showed an inverse relationship between effect and
duration of balding. Males with duration of balding <5 years
showed a significantly better effect than those with duration
of balding >21 years. Females, in contrast, showed no
correlation with duration of balding. The diameter of vertex
balding in men showed an inverse relationship with efficacy
of minoxidil. Males with <5cm diameter vertex balding area
showed a better effect of treatment than subjects with
diameters >15cm. Finally, duration of hair loss less than
one year compared with more than 10 years at onset of
treatment resulted in a significantly more effective treatment
with respect to stabilization of alopecia and new hair growth.
Finasteride, an inhibitor of type 2 5α-reductase, inhibits
conversion of testosterone to DHT, resulting in decrease in
serum and scalp DHT levels believed to be pathogenic in
AGA. 1mg oral finasteride daily has been shown to be
effective in prevention and treatment of hair loss in men
(Kaufman 1996; Kaufman et al 1998; Leyden et al 1999;
FMPHL 2003), and has also shown some effect in aging
males (Brenner and Matz 1999; Whiting et al 2003).
Traditionally, pattern hair loss in women has successfully
been treated with topical minoxidil, and with systemic
antiandrogens, such as cyproterone acetate or spironolactone
(Sinclair et al 2005), though the efficacy of the latter has
also been challenged, at least in premenopausal women with
normal androgen levels (Vexiau et al 2002). While oral
finasteride has unanimously been shown to be effective in
treatment of hair loss in men, its efficacy in women has
remained controversial (Whiting et al 1999; Price et al 2000;
Shum et al 2002; Thai and Sinclair 2002; Carmina and Lobo
2003; Trüeb and STSG 2004). Due to inconsistent data with
respect to efficacy of finasteride in women, it has been
suggested that not all types of female hair loss have the same
pathophysiology, ie, a distinction should be made between
alopecia with early or late (postmenopausal) onset, and with
or without hyperandrogenemia (Olsen, Hordinsky, et al
2002). Due to teratogenicity for the male fetus, finasteride
is contraindicated for use in premenopausal women.
Photoprotection of hair and scalp
Awareness of sun protection has become imperative as a
consequence of increased leisure time with a growing
popularity of outdoor activities and holidays in the sun.
Topically applied chemicals that act as sun protectors are
widely utilized and offer the most convenient means of
protecting the glabrous skin against acute (sunburn) and
chronic pathologic effects of UVR. Their use on the hair-
bearing scalp is problematic for cosmetic reasons, unless
complete baldness is present. Although hats provide the best
protection of the scalp from UVR, not all patients find them
convenient or acceptable for this purpose. While protection
of the hair against photodamage has been extensively
studied, there are no data on photoprotection of the hair-
bearing scalp. It has been found that hair dyes may protect
hair against photodamage (Pande et al 2001); recentClinical Interventions in Aging 2006:1(2) 128
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experimental work indicate that cinnamidpropyltrimonium
chloride, a quaternized UV absorber, delivered from a
shampoo system, is suitable for photoprotection of hair,
while simultaneously providing an additional conditional
benefit on hair (Gao and Bedell 2001); and solid lipid
nanoparticles have been developed as novel carriers of UV
blockers for the use on skin and hair, while offering
photoprotection on their own by reflecting and scattering
UVR (Wissing and Muller 2001). Finally, systemic
photoprotection has been the focus of more recent
investigation, in as much as this would overcome some of
the problems associated with the topical use of sunscreens:
Preclinical studies illustrate photoprotective properties of
supplemented antioxidants, particularly beta-carotene (pro-
vitamin A), α-tocopherol (vitamin E), and L-ascorbate
(vitamin C). However, clinical evidence that these prevent,
retard, or slow down solar skin damage is impending. The
same applies to topical melatonin, which has been found to
suppress UV-induced erythema, and UV-induced reactive
oxygen species in a dose-dependent manner (Bangha et al
1996). Nevertheless, these results suggest the probable utility
of combining these compounds with known sunscreens to
maximize photoprotection.
Anti-aging compounds
Recent advances in the care of aging hair and scalp are “anti-
aging” compounds. Due to water dilution and short contact
time, anti-aging compounds do not have any effect in
shampoos. Antioxidants in shampoos, such as vitamin C
and E, protect fatty substances in the shampoo from
oxidation, and not the scalp. Topical anti-aging compounds
of current interest are green tea polyphenols, selenium,
copper, phytoestrogens, melatonin, and as yet unidentified
substances from traditional Chinese medicine (TCM), and
Ayurvedic medicine.
In the course of hormonal anti-aging protocols containing
recombinant human growth hormone at the Palm Springs
Life Extension Institute, Chein (1998) reports improvement
of hair thickness and structure in 38% of patients, in some
cases darkening of hair, and in few increased hair growth. It
is noteworthy that in primary growth hormone insensitivity
(Laron syndrome), hair growth, and hair structure (but not
hair color) have been shown to be impaired (Lurie et al
2004).
Future directions
There is an increasing interest in the hair follicular route for
delivery of active compounds affecting the hair. Current
research activities focus on topical liposome targeting for
melanins, genes, and proteins selectively to hair follicles
for therapeutic and cosmetic modification of hair (Hoffman
1998). For example, topical liposome selective delivery to
hair follicles has demonstrated the ability to color hair with
melanin. Finally, yet another line of research in the quest of
new treatments for hair loss is tissue engineering with cells
of hair follicular origin with inductive properties (Reynolds
et al 1999).
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